BioCentury | Jan 5, 2018
Clinical News

VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

...survival (PFS), combined CA-125 and RECIST 1.1 response (GCIG criteria) and patient reported outcome measures. Gynecologic Oncology Group (GOG) Foundation Inc....
Items per page:
1 - 1 of 1
BioCentury | Jan 5, 2018
Clinical News

VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

...survival (PFS), combined CA-125 and RECIST 1.1 response (GCIG criteria) and patient reported outcome measures. Gynecologic Oncology Group (GOG) Foundation Inc....
Items per page:
1 - 1 of 1